IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases

Antibodies against the B cell-specific antigens CD20 and CD19 have markedly improved the treatment of B cell-derived lymphoma and autoimmune diseases by depleting malignant and autoreactive B cells. However, since CD20 and CD19 are also expressed on healthy B cells, such antibodies lack disease spec...

Full description

Bibliographic Details
Main Authors: Sebastian Hörner, Moustafa Moustafa-Oglou, Karin Teppert, Ilona Hagelstein, Joseph Kauer, Martin Pflügler, Kristina Neumann, Hans-Georg Rammensee, Thomas Metz, Andreas Herrmann, Helmut R. Salih, Gundram Jung, Latifa Zekri
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
bispecific antibodies
lymphoma
autoimmune diseases
apoptosis
CD20
CD19
Online Access:https://www.mdpi.com/2072-6694/14/16/3941

Internet

https://www.mdpi.com/2072-6694/14/16/3941

Similar Items